{"id":"clopidogrel-active-metabolite","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bleeding"},{"rate":"1-2","effect":"Dyspnea"},{"rate":"1-2","effect":"Chest pain"},{"rate":"1-2","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1201398","moleculeType":"Small molecule","molecularWeight":"341.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a prodrug that requires hepatic metabolism to generate its active thiol metabolite, which then binds covalently to the P2Y12 receptor on platelet surfaces. This binding blocks ADP-induced platelet activation and aggregation, reducing the risk of thrombotic events. The active metabolite is responsible for the antiplatelet efficacy of clopidogrel in cardiovascular disease.","oneSentence":"Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:32.514Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Percutaneous coronary intervention with stent placement"},{"name":"Stroke prevention in patients with recent myocardial infarction or stroke"}]},"trialDetails":[{"nctId":"NCT03496506","phase":"PHASE1","title":"A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-03-05","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT03774394","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-08-22","conditions":"Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)","enrollment":61},{"nctId":"NCT04630288","phase":"","title":"Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2019-07-02","conditions":"Acute Coronary Syndromes","enrollment":1900},{"nctId":"NCT02302508","phase":"PHASE4","title":"Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-09-01","conditions":"Diabetes","enrollment":""},{"nctId":"NCT01263093","phase":"PHASE1","title":"A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":47},{"nctId":"NCT02008123","phase":"PHASE2","title":"Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant","status":"WITHDRAWN","sponsor":"Dent Neuroscience Research Center","startDate":"2013-08","conditions":"Clopidogrel Resistance, Secondary Stroke Prevention","enrollment":""},{"nctId":"NCT01421706","phase":"PHASE1","title":"Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects","status":"COMPLETED","sponsor":"Inje University","startDate":"2008-07","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix"],"phase":"marketed","status":"active","brandName":"Clopidogrel active metabolite","genericName":"Clopidogrel active metabolite","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Stroke prevention in patients with recent myocardial infarction or stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}